America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide.
America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. Medicines in development, which are all in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Some of the reported initiatives being taken against diabetes include treatments to improve glucose-dependent insulin secretion for type 2 diabetes and to stimulate and enhance the regeneration of insulin-producing cells for type 1 diabetes.
A new public-private partnership involving the National Institutes of Health, 10 biopharmaceutical companies, PhRMA, and several non-profit disease foundations aims to transform the current model for developing new diagnostics and treatments for certain diseases. The Accelerating Medicines Partnership will begin with three- to five-year pilot projects focused on three disease areas, including diabetes.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.